Advanced Search
HUANG Zhen, CHEN Lulu, SONG Qibin. Advances in Cost Economics of Radiation Therapy and Thoracic Surgery for Early-Stage Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(4): 263-273. DOI: 10.3971/j.issn.1000-8578.2025.24.1056
Citation: HUANG Zhen, CHEN Lulu, SONG Qibin. Advances in Cost Economics of Radiation Therapy and Thoracic Surgery for Early-Stage Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2025, 52(4): 263-273. DOI: 10.3971/j.issn.1000-8578.2025.24.1056
shu

Advances in Cost Economics of Radiation Therapy and Thoracic Surgery for Early-Stage Lung Cancer

  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China

Funding: 

National Natural Science Foundation of China (No. 82102841, 82273094); Hubei Provincial Natural Science Foundation General Project (No. JCZRYB202500783); 2024 Wuhan University School of Medicine Teaching Program (No. 2024YB12)

undefined

More Information
  • Corresponding author:

    SONG Qibin, E-mail: qibinsong@whu.edu.cn

    CHEN Lulu, E-mail: chenlulu@whu.edu.cn

  • Received Date: October 28, 2024
  • Revised Date: February 07, 2025
  • Accepted Date: February 10, 2025
  • Available Online: February 16, 2025
    Graphical Abstract
    • Abstract

  • The cost economics of early-stage lung cancer treatments is a key focus in the field of lung cancer. The primary treatment modalities for early-stage lung cancer include radiotherapy and thoracic surgery, each offering distinct advantages in therapeutic outcomes and costs. To better understand the cost-effectiveness of radiotherapy versus thoracic surgery for early-stage lung cancer, this paper reviews the progress of recent research on economic evaluations of these two treatment approaches.

    • FullText(HTML)

  • Competing interests: The authors declare that they have no competing interests.

    • References (54)
  • [1]
    Forde PM, Spicer J, LU S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985. doi: 10.1056/NEJMoa2202170
    [2]
    Abdelaziz HM, Gaber M, Abd-Elwakil MM, et al. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates[J]. J Control Release, 2018, 269: 374-392. doi: 10.1016/j.jconrel.2017.11.036
    [3]
    Jovanoski N, Bowes K, Brown A, et al. Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence[J]. Lung Cancer Manag, 2023, 12(3): LMT60. doi: 10.2217/lmt-2023-0003
    [4]
    Vachani A, Carroll NM, Simoff MJ, et al. Stage Migration and Lung Cancer Incidence After Initiation of Low-Dose Computed Tomography Screening[J]. J Thoracic Oncol, 2022, 17(12): 1355-1364. doi: 10.1016/j.jtho.2022.08.011
    [5]
    Leleu O, Storme N, Basille D, et al. Lung cancer screening by low-dose CT scan in France: final results of the DEP KP80 study after three rounds[J]. EBioMedicine, 2024, 109: 105396. doi: 10.1016/j.ebiom.2024.105396
    [6]
    US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA, 2021, 325(10): 962-970. doi: 10.1001/jama.2021.1117
    [7]
    Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21): 3552-3559. doi: 10.1200/JCO.2007.13.9030
    [8]
    Mcgarry RC, Song G, des Rosiers P, et al. Observation-only management of early stage, medically inoperable lung cancer: poor outcome[J]. Chest, 2002, 121(4): 1155-1158. doi: 10.1378/chest.121.4.1155
    [9]
    Alduais Y, Zhang H, Fan F, et al. Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment[J]. Medicine(Baltimore), 2023, 102(8): e32899.
    [10]
    Zhang Z, Zhang Y, Feng H, et al. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis[J]. Eur J Cardiothoracic Surg, 2013, 44(3): 407-414. doi: 10.1093/ejcts/ezt015
    [11]
    Jindani R, Rodriguez-Quintero JH, Kamel M, et al. Trends and Disparities in Robotic Surgery Utilization for Non-Small Cell Lung Cancer[J]. J Surg Res, 2024, 302: 24-32. doi: 10.1016/j.jss.2024.07.008
    [12]
    周追求, 周宇轩, 曾俊, 等. 机器人辅助与胸腔镜辅助胸外科手术在非小细胞肺癌中的疗效对比[J]. 中华医学杂志, 2024, 104(34): 3221-3227. [Zhou ZQ, Zhou YX, Zeng J, et al. Comparison of the efficacy of robot assisted and thoracoscopic assisted thoracic surgery in non-small cell lung cancer[J]. Zhonghua Yi Xue Za Zhi, 2024, 104(34): 3221-3227.] doi: 10.3760/cma.j.cn112137-20240226-00410

    Zhou ZQ, Zhou YX, Zeng J, et al. Comparison of the efficacy of robot assisted and thoracoscopic assisted thoracic surgery in non-small cell lung cancer[J]. Zhonghua Yi Xue Za Zhi, 2024, 104(34): 3221-3227. doi: 10.3760/cma.j.cn112137-20240226-00410
    [13]
    Haasbeek CJA, Palma D, Visser O, et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands[J]. Ann Oncol, 2012, 23(10): 2743-2747. doi: 10.1093/annonc/mds081
    [14]
    Senthi S, Lagerwaard FJ, Haasbeek CJA, et al. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis[J]. Lancet Oncol, 2012, 13(8): 802-809. doi: 10.1016/S1470-2045(12)70242-5
    [15]
    Sher DJ, Wee JO, Punglia RS. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(5): e767-e774. doi: 10.1016/j.ijrobp.2010.10.074
    [16]
    Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ non-small-cell lung cancer patients treated with stereotactic body radiotherapy[J]. J Clin Oncol, 2009, 27(20): 3290-3296. doi: 10.1200/JCO.2008.21.5681
    [17]
    Puri V, Crabtree TD, Kymes S, et al. A comparison of surgical intervention and stereotactic body radiation therapy for stage Ⅰ lung cancer in high-risk patients: A decision analysis[J]. J Thorac Cardiovasc Surg, 2012, 143(2): 428-436. doi: 10.1016/j.jtcvs.2011.10.078
    [18]
    Shah A, Hahn SM, Stetson RL, et al. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage Ⅰ non-small cell lung cancer[J]. Cancer, 2013, 119(17): 3123-3132. doi: 10.1002/cncr.28131
    [19]
    Louie AV, Rodrigues GB, Palma DA, et al. Measuring the Population Impact of Introducing Stereotactic Ablative Radiotherapy for Stage Ⅰ Non-Small Cell Lung Cancer in Canada[J]. Oncologist, 2014, 19(8): 880-885. doi: 10.1634/theoncologist.2013-0469
    [20]
    Smith BD, Jiang J, Chang JY, et al. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults[J]. J Geriatr Oncol, 2015, 6(4): 324-331. doi: 10.1016/j.jgo.2015.05.002
    [21]
    Paix A, Noel G, Falcoz PE, et al. Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer[J]. Radiother Oncol, 2018, 128(3): 534-540. doi: 10.1016/j.radonc.2018.04.013
    [22]
    Wolff HB, Alberts L, van der Linden N, et al. Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage Ⅰ non-small cell lung cancer: A modeling study[J]. Lung Cancer, 2020, 141: 89-96. doi: 10.1016/j.lungcan.2020.01.011
    [23]
    Santos MA, Oliveira E Silva LF, Reis Neto JP, et al. A Cost-Effectiveness Study of Stereotactic-Body Radiation Therapy Compared to Surgery in Patients with Early Non-Small Cell Lung Cancer, from the Perspective of the Brazilian Private Health-Care System[J]. Int J Radiat Oncol Biol Phys, 2022, 114(3): e389.
    [24]
    Igarashi A, Onishi H, Shioyama Y, et al. Cost-Utility Analysis of Stereotactic Body Radiation Therapy Versus Surgery for Patients With Stage Ⅰ Non-small Cell Lung Cancer in Japan[J]. Int J Radiat Oncol Biol Phys, 2025, 121(1): 56-57. doi: 10.1016/j.ijrobp.2024.07.2328
    [25]
    Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis[J]. Ann Thorac Surg, 2012, 93(4): 1027-1032. doi: 10.1016/j.athoracsur.2011.06.007
    [26]
    Morias S, Marcu LG, Short M, et al. Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy[J]. J Oncol, 2018, 2018: 6483626.
    [27]
    Chang JY, Senan S, Paul MA, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials[J]. Lancet Oncol, 2015, 16(6): 630-637. doi: 10.1016/S1470-2045(15)70168-3
    [28]
    Onishi H, Shioyama Y, Matsumoto Y, et al. Japanese Multi-institutional Study of Stereotactic Body Radiation Therapy for 661 Medically Operable Patients With Stage I Non-Small Cell Lung Cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 93(3): S187.
    [29]
    Okami J, Shintani Y, Okumura M, et al. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18, 973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010[J]. J Thorac Oncol, 2019, 14(2): 212-222. doi: 10.1016/j.jtho.2018.10.002
    [30]
    Moghanaki D, Karas T. Surgery versus SABR for NSCLC[J]. Lancet Oncol, 2013, 14(12): e490-e491. doi: 10.1016/S1470-2045(13)70445-5
    [31]
    Akhtar-Danseh GG, Akhtar-Danesh N, Finley C. Uptake and survival effects of minimally invasive surgery for lung cancer: A population-based study[J]. Eur J Surg Oncol, 2021, 47(7): 1791-1796. doi: 10.1016/j.ejso.2021.01.002
    [32]
    Bucknell NW, Belderbos J, Palma DA, et al. Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective[J]. J Thorac Oncol, 2022, 17(8): 961-973. doi: 10.1016/j.jtho.2022.05.003
    [33]
    Shirvani SM, Jiang J, Chang JY, et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly[J]. Int J Radiat Oncol Biol Phys, 2012, 84(5): 1060-1070. doi: 10.1016/j.ijrobp.2012.07.2354
    [34]
    Crabtree TD, Denlinger CE, Meyers BF, et al. Stereotactic body radiation therapy versus surgical resection for stage Ⅰ non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2010, 140(2): 377-386. doi: 10.1016/j.jtcvs.2009.12.054
    [35]
    Detillon DDEMA, Driessen EJM, Aarts MJ, et al. Changes in treatment patterns and survival in elderly patients with stage Ⅰ non–small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery[J]. Eur J Cancer, 2018, 101: 30-37. doi: 10.1016/j.ejca.2018.06.016
    [36]
    Chen H, Laba JM, Boldt RG, et al. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies[J]. Int J Radiat Oncol Biol Phys, 2018, 101(1): 186-194. doi: 10.1016/j.ijrobp.2018.01.064
    [37]
    Cao C, Wang D, Chung C, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer[J]. J Thorac Cardiovasc Surg, 2019, 157(1): 362-373. e8.
    [38]
    Snider M, Salama JK, Boyer M. Survival and recurrence rates following SBRT or surgery in medically operable Stage Ⅰ NSCLC[J]. Lung Cancer, 2024, 197: 107962. doi: 10.1016/j.lungcan.2024.107962
    [39]
    Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2006, 4(6): 548-582. doi: 10.6004/jnccn.2006.0046
    [40]
    Mcneil BJ, Weichselbaum R, Pauker SG. Fallacy of the five-year survival in lung cancer[J]. N Engl J Med, 1978, 299(25): 1397-1401. doi: 10.1056/NEJM197812212992506
    [41]
    van der Voort van Zyp NC, Prévost JB, van der Holt B, et al. Quality of life after stereotactic radiotherapy for stage Ⅰ non-small-cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2010, 77(1): 31-37. doi: 10.1016/j.ijrobp.2009.04.080
    [42]
    Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation[J]. Radiat Oncol, 2008, 3: 36. doi: 10.1186/1748-717X-3-36
    [43]
    Dahele M, Palma D, Lagerwaard F, et al. Radiological changes after stereotactic radiotherapy for stage Ⅰ lung cancer[J]. J Thorac Oncol, 2011, 6(7): 1221-1228 doi: 10.1097/JTO.0b013e318219aac5
    [44]
    Widder J, Postmus D, Ubbels JF, et al. Survival and quality of life after stereotactic or 3D-conformal radiotherapy for inoperable early-stage lung cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): e291-297. doi: 10.1016/j.ijrobp.2011.03.052
    [45]
    Iovoli AJ, Yu B, Ma SJ, et al. Quality of Life After Stereotactic Body Radiation Therapy or Surgery for Early-Stage NSCLC: A Systematic Review[J]. JTO Clin Res Rep, 2022, 3(11): 100417.
    [46]
    Win T, Sharples L, Wells FC, et al. Effect of lung cancer surgery on quality of life[J]. Thorax, 2005, 60(3): 234-238. doi: 10.1136/thx.2004.031872
    [47]
    Dales RE, Bélanger R, Shamji FM, et al. Quality-of-life following thoracotomy for lung cancer[J]. J Clin Epidemiol, 1994, 47(12): 1443-1449. doi: 10.1016/0895-4356(94)90088-4
    [48]
    Jiang S, Wang B, Zhang M, et al. Quality of life after lung cancer surgery: sublobar resection versus lobectomy[J]. BMC Surg, 2023, 23(1): 353. doi: 10.1186/s12893-023-02259-1
    [49]
    Kenny PM, King MT, Viney RC, et al. Quality of life and survival in the 2 years after surgery for non small-cell lung cancer[J]. J Clin Oncol, 2008, 26(2): 233-241. doi: 10.1200/JCO.2006.07.7230
    [50]
    Ali MK, Ewer MS, Atallah MR, et al. Regional and overall pulmonary function changes in lung cancer. Correlations with tumor stage, extent of pulmonary resection, and patient survival[J]. J Thorac Cardiovasc Surg, 1983, 86(1): 1-8. doi: 10.1016/S0022-5223(19)39202-5
    [51]
    Rogers ML, Duffy JP. Surgical aspects of chronic post-thoracotomy pain[J]. Eur J Cardiothorac Surg, 2000, 18(6): 711-716. doi: 10.1016/S1010-7940(00)00569-8
    [52]
    Gotoda Y, Kambara N, Sakai T, et al. The morbidity, time course and predictive factors for persistent post-thoracotomy pain[J]. Eur J Pain, 2001, 5(1): 89-96. doi: 10.1053/eujp.2001.0225
    [53]
    Tibdewal A, Pathak RS, Agarwal JP, et al. Nodal recurrences after stereotactic body radiotherapy for early stage non-small-cell lung cancer[J]. Curr Probl Cancer, 2021, 45(2): 100653. doi: 10.1016/j.currproblcancer.2020.100653
    [54]
    Wisnivesky JP, Mudd J, Stone K, et al. Longitudinal quality of life after sublobar resection and stereotactic body radiation therapy for early-stage non-small cell lung cancer[J]. Cancer, 2024, 130(14): 2515-2527. doi: 10.1002/cncr.35286
    • Related Articles

  • Cited by

    Periodical cited type(1)

    1. 秦汝男，刘保峰，李旭东，李培，曾强. 不同类型程序性细胞死亡在苯致血液毒性作用中的研究进展. 现代预防医学. 2024(08): 1390-1395+1419 .

    Other cited types(1)

Catalog

    Tables(1)

    Get Citation
    PDF
    XML
    Article views (874) PDF downloads (239) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：14863382 Visits today：267

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return